Fri.Feb 23, 2024

article thumbnail

Travere's Filspari, J&J's Carvykti win support from CHMP in blitz of positive recommendations

Fierce Pharma

A narrow miss in a confirmatory trial has | Along with host of other positive recommendations, European drug regulators rendered a positive opinion on Travere's Filspari for full approval in Berger’s disease.

282
282
article thumbnail

AI in Pharma: Navigating New Frontiers in Drug Discovery and Development

Pharma IQ

Bringing a new drug to market typically takes a decade or more and approximately US$2.5 billion. However, new technology, including AI, can dramatically shorten the drug discovery process and reduce t.

Pharma 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

To BioMarin CEO Alexander Hardy, hemophilia A gene therapy Roctavian needs 3 stars to align

Fierce Pharma

Even Alexander Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian.

article thumbnail

The AI-Powered Path to Revolutionising Rare Disease Research

Pharma IQ

Explore how AI/ML can accelerate rare disease research and clinical trials, by enhancing inclusivity and efficiency, to deliver new drugs and therapeutics to patients. With insights from Dr. Harsha Ra.

Patients 130
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Congressional lawmakers strike back at Biden admin's 'march-in' proposal to corral drug costs

Fierce Pharma

As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission (FTC), a group of lawmakers on both sides of the aisle have war | As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission, a small group of lawmakers on both sides of the aisle have warned the approach could “hamstring” U.S. innovation.

242
242
article thumbnail

‘Nation-State’ Cyberattack Hits Change Healthcare, Disrupting Pharmacy Services Across the Country

MedCity News

Pharmacies across the country are facing disruptions following a cyberattack on Change Healthcare — which is owned by Optum, a subsidiary of UnitedHealth Group. In a filing with the SEC, UnitedHealth stated that the unauthorized party that gained access to Change Healthcare’s systems was a “suspected nation-state associated cyber security threat actor.

More Trending

article thumbnail

Driving Accessibility in HealthTech: 3 Things Founders should Consider for Thoughtful AI Implementation in 2024

MedCity News

The benefits of artificial intelligence in healthcare are apparent. With careful planning, we can ensure that these developments benefit everyone, leaving no one behind in the goal of a healthier and more equal future.

article thumbnail

Oncopeptides' Pepaxto reaches end of the line in US after FDA yanks approval

Fierce Pharma

Following a contentious advisory committee meeting and an FDA request for the withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. | Following a contentious advisory committee meeting and an FDA request for withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. market in late 2022, the other shoe has dropped.

FDA 232
article thumbnail

For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

PharmaVoice

Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

105
105
article thumbnail

'The Top Line': Breaking down Eli Lilly’s ESG formula

Fierce Pharma

This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Bavarian Nordic gets swift EU review of chikungunya shot

pharmaphorum

Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva. The Danish pharma group said it is planning to file for approval of its vaccine in the first half of this year, adding the EU regulator’s human medicine committee, the CHMP, has said it will cut the review time from 210 to 150 days under its accelerated assessment procedure.

Medicine 124
article thumbnail

Is AI in Prior Authorization Promising or Dangerous?

MedCity News

AI can improve the prior authorization process, but there needs to be more transparency, experts said during a recent panel held by KFF.

120
120
article thumbnail

Analysis reveals “superior efficacy” of long-acting injectable HIV treatment

European Pharmaceutical Review

An interim analysis of a Phase III trial has demonstrated superior efficacy of the long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva ( cabotegravir + rilpivirine), for HIV patients with a history of ART adherence challenges. “The interim data indicating the superiority of long-acting therapy compared to daily oral therapy in individuals who have difficulty taking pills for HIV every day is a remarkable outcome,” shared Dr Kimberly Smith, MPH, Head of R&D at ViiV Healt

article thumbnail

Identifying Trends Surrounding the Use of In-House Pharmacies for High-Cost Drugs

Pharmaceutical Commerce

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

104
104
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AbbVie announces its new CEO

European Pharmaceutical Review

AbbVie’s current President and Chief Operating Officer (COO) is set to replace the company’s existing CEO later this year. Robert Michael will become AbbVie’s new CEO on 1 July 2024. Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted.

article thumbnail

FDA will decide in June on Dupixent for COPD

pharmaphorum

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new treatment for the widespread and life-threatening disease in over a decade.

FDA 111
article thumbnail

FDA generic drug approvals rose in 2023 in bid for improved access

Pharmaceutical Technology

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

FDA 105
article thumbnail

AI improves adenoma detection in colonoscopies

pharmaphorum

AI software developed by Israeli medtech Magentiq-Eye has been shown to improve detection rates for adenoma, a precursor to colorectal cancer, in colonoscopy procedures

117
117
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact

MedCity News

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.

article thumbnail

After Roche’s exit, Blueprint passes Gavreto on to Rigel

pharmaphorum

After losing Roche as a partner, Blueprint Medicines has sold US commercial rights to RET inhibitor Gavreto to Rigel Pharma in a deal worth up to $117.

Medicine 105
article thumbnail

Network With Healthcare Investors at MedCity INVEST 2024!

MedCity News

The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!

article thumbnail

CSL, Travere close on EU approval of IgAN drug sparsentan

pharmaphorum

Travere and partner CSL Vifor close on EU approval of sparsentan for rare kidney disease IgA nephropathy, after CHMP's positive opinion on the drug.

104
104
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

NHS offers preventative bowel cancer screening for patients with Lynch syndrome

PharmaTimes

In England, around 1,100 cases of bowel cancer are caused by the inherited condition every year

article thumbnail

Navigating the Future: Experts Discuss the Intersection of Copyright, AI, and Innovation in Upcoming Virtual Town Hall

Copyright Clearance Center

The post Navigating the Future: Experts Discuss the Intersection of Copyright, AI, and Innovation in Upcoming Virtual Town Hall appeared first on Copyright Clearance Center.

59
article thumbnail

AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis

PharmaTimes

The immunosuppressant reduced inflammation in patients with the skin condition after three days

article thumbnail

Nixon Law Group Expands Corporate, Mergers and Acquisitions, Venture Capital, and Health Tech Capabilities with Four New Attorneys

Nixon Gwilt Law

Nixon Law Group (NLG) is excited to announce a significant expansion of our core capabilities through the addition of four attorneys with expertise in healthcare technology , mergers and acquisitions , fundraising and venture capital , and corporate/business counsel. These new team members collectively add decades of experience working with healthcare innovation companies of all sizes, greatly expanding our capacity to serve new and existing clients’ needs in these areas.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

How hospitals can enhance operational efficiency with data analytics

Clarify Health

Hospitals that effectively leverage healthcare data analytics benefit from having access to precise insights that help lead to better decisions for patients and the hospital’s bottom line. Healthcare data comes from countless places, including claims, clinical outcomes, and administrative data, plus patient surveys, electronic health records, pharmaceutical data, patient registries, and clinical trials.

article thumbnail

Exploring Pharmaceutical Sales Reps Salaries: A Deep Dive

Rep-Lite

As a pharmaceutical sales rep, you undergo a rigorous training program, develop strong relationships with healthcare professionals, and work tirelessly to meet sales targets. You also deal with the challenges of an ever-changing industry landscape, including stiff competition from generic drugs and strict regulation policies. Despite these challenges, pharmaceutical sales reps play a crucial role in driving revenue for their companies and promoting life-saving medication to patients.

article thumbnail

Nixon Gwilt Law Expands Corporate, M&A, and Venture Capital Capabilities with Four New Attorneys

Nixon Gwilt Law

Nixon Gwilt Law (NGL) is excited to announce a significant expansion of our core capabilities through the addition of four attorneys with expertise in healthcare mergers and acquisitions , fundraising and venture capital , and corporate/business counsel. These new team members collectively add decades of experience working with healthcare innovation companies of all sizes, greatly expanding our capacity to serve new and existing clients’ needs in these areas.

article thumbnail

World Health Organization Grants Prequalification to Typhoid Conjugate Vaccine

Pharmaceutical Commerce

SKYTyphoid, a single-dose typhoid conjugate vaccine jointly developed by SK bioscience and the International Vaccine Institute, showed a positive immunogenicity and safety profile across age groups.

Safety 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A